Neptune Wellness Solutions (NEPT) – Globe Newswire
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
-
NEPT ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Neptune Wellness Solutions Inc. – NEPT
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Plug Power, XL Fleet Corp., Bellus Health, and Neptune Wellness and Encourages Investors to Contact the
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
-
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
-
Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General
-
Acasti Announces Review Process of Strategic Alternatives
-
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
-
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
-
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
-
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
-
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
-
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
-
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
-
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
-
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
-
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
-
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
-
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
-
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
-
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
-
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
-
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
-
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
-
Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
-
Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes
-
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020
-
Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal
-
Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call
-
Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®
-
Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
-
Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity
-
Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th
-
Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM
-
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
-
Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
-
Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
-
Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital
Back to NEPT Stock Lookup